MEDVi QUAD ED Reviews 2026: Quad by Medvi Verification Guide
As more adults compare private online healthcare options in 2026, this Quad by Medvi review explores how MEDVi QUAD is positioned for provider-guided telehealth access, what buyers should verify before enrollment, and which pricing, pharmacy, cancellation, and compounded-medication factors may influence the experience.
NEWARK, Del., June 29, 2026 (Newswire.com) - Advertorial Disclosure: This content is for informational and advertising purposes and contains affiliate links. If a purchase or enrollment is completed through links in this content, a commission may be earned at no additional cost to the reader. MEDVi QUAD is associated with a telehealth prescription process. Prescription medication is available only after consultation with and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed. Compounded medications are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness, or quality before marketing. This content is not medical advice, diagnosis, or treatment.
View MEDVi QUAD Program Details
If MEDVi QUAD, also searched as Quad by Medvi, caught your attention, the next step is not to guess from an ad. It is to verify the few details that can actually affect the decision: price, provider approval, pharmacy fulfillment, cancellation terms, and compounded-medication disclosures.
TL;DR: MEDVi QUAD, also searched as Quad by Medvi, is a telehealth prescription program for adults comparing private online prescription options. The official page presents QUAD as a clinician-reviewed program with a private intake process, listed compounded-medication components, displayed monthly pricing, customer support details, and discreet delivery if approved. The smart buyer move is simple: verify the final checkout price, provider-review process, pharmacy role, cancellation path, and compounded-medication disclosure before enrolling.
You saw an ad for MEDVi QUAD or Quad by Medvi and started searching before submitting payment. That is the right move with any telehealth prescription program, especially one involving provider review, recurring monthly pricing, pharmacy fulfillment, and compounded-medication disclosures. This guide focuses on what buyers can verify before enrollment: what MEDVi says QUAD is, how the intake process works, what the current pricing page displays, what the terms say about medical decision-making, and what questions should be answered before moving forward. The best time to verify those details is before the first payment screen, not after a billing, approval, or fulfillment question appears.
MEDVi QUAD Consumer Research 2026: Quad by Medvi Verification Guide
Quick Verification Snapshot: What to Check Before Payment
Product name: MEDVi QUAD
Common search variant: Quad by Medvi
Category: Telehealth prescription program
Official website: https://quad.medvi.org/
Affiliate access link: https://communityhealthcarenetwork.org/quad-by-medvi
Displayed pricing: The official page displayed $114/month at the time reviewed, with $179/month shown as a reference price.
Listed program features: Doctor consultation included, free rush shipping, 24/7 medical support, and cancel anytime.
Listed components: Apomorphine, vardenafil, tadalafil, and sildenafil.
Contact email: hello@medvi.org
Phone: +1-585-312-4226
Mailing address: 131 Continental Dr. Ste 305, Newark, DE 19713 USA
Buyer takeaway: MEDVi QUAD is best evaluated as a telehealth prescription pathway, not as a simple retail product. The most important question is not whether the page sounds appealing. The more useful question is whether the buyer understands the provider-review process, pharmacy role, pricing terms, and compounded-medication disclosure before enrolling.
5 Things to Verify Before Enrollment
Before enrolling in MEDVi QUAD, or Quad by Medvi as some buyers search it, readers should verify five details that can affect the decision: the final checkout price, whether provider approval is required before fulfillment, which pharmacy may dispense the prescription if approved, what cancellation requires, and how the compounded-medication disclosure applies to the program.
Price: Confirm the final checkout amount, billing frequency, and whether future charges can change.
Approval: Confirm that a licensed provider reviews the intake and that approval is not guaranteed.
Pharmacy: Ask which pharmacy may fulfill the prescription if approved and whether it is licensed to ship to the buyer's state.
Cancellation: Confirm whether cancellation requires portal messaging, email, phone, or advance notice before the next billing cycle.
Compounded-medication disclosure: Confirm that the buyer understands compounded medications are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Buyer takeaway: The decision does not have to be rushed, but it should be verified before payment. These five checks help buyers separate the ad from the actual enrollment terms.
View MEDVi QUAD Program Details
What Is MEDVi QUAD?
Quick answer: MEDVi QUAD, also searched as Quad by Medvi, is a telehealth prescription program promoted through MEDVi for adults comparing private online prescription options. The official page presents QUAD as a clinician-reviewed program with an online intake, provider review, listed compounded-medication components, and discreet delivery if approved.
MEDVi QUAD is designed for readers who want a private way to begin a telehealth evaluation without starting with an in-person office visit. The official page describes a short online intake process, review by a U.S.-licensed doctor, and discreet shipping after approval. That structure is one reason the program attracts search interest from buyers comparing MEDVi QUAD reviews, Quad by Medvi reviews, pricing, complaints, customer support, and cancellation terms.
Because buyers may search both MEDVi QUAD and Quad by Medvi, this verification guide uses both names while referring to the same official program.
The important distinction is that MEDVi QUAD should not be treated like a typical wellness supplement or ordinary online checkout product. It is associated with a prescription pathway. That means a buyer's health history, medication list, eligibility, and provider review matter.
For a serious buyer, that can be a useful structure. A clinician-reviewed process creates a clearer pathway than a no-review purchase page. But it also means buyers should not assume approval, final pricing, pharmacy fulfillment, or any specific prescription decision until the provider-review process is complete.
Buyer takeaway: MEDVi QUAD may appeal to adults who want privacy, convenience, and an online provider-review process. The right way to evaluate it is through verification: price, provider approval, pharmacy fulfillment, terms, cancellation, and medical appropriateness.
How MEDVi's Telehealth Intake Process Works
The official MEDVi QUAD page describes a three-step process. First, the buyer answers questions through an online intake form. Second, a U.S.-licensed doctor reviews the case. Third, if approved, the order is shipped discreetly.
That process is simple on the surface, but each step matters. The intake form is where the buyer provides health information. The provider review is where clinical appropriateness is evaluated. The fulfillment stage is where the pharmacy role becomes important if a prescription is approved.
In plain English, the buyer is not just buying a bottle from a shelf. The buyer is entering a telehealth process where the final decision depends on medical review. That is why buyers should provide complete and accurate information, including current medications, health conditions, allergies, prior adverse reactions, and any provider instructions they have already received.
MEDVi's terms describe the platform as supporting intake, health information collection, administrative coordination, payment, and technology access. The terms also separate MEDVi's platform role from the healthcare services provided by independent medical providers. That separation matters because the clinical decision should come from a licensed provider, not the marketing page.
Quick answer: MEDVi's intake process starts with an online questionnaire, then moves to provider review. If a licensed provider determines the program is clinically appropriate, fulfillment may proceed through a pharmacy. Completing the intake does not guarantee approval.
What Kind of Medication Pathway Does MEDVi QUAD Involve?
The official page lists apomorphine, vardenafil, tadalafil, and sildenafil as components associated with the QUAD compounded prescription program. This article does not compare those components, rank them against alternatives, or make an independent claim about clinical performance. Buyers should confirm the exact formulation, strength, dosage form, pharmacy, instructions, risks, and clinical appropriateness directly with the reviewing provider and dispensing pharmacy if approved.
This is one of the most important parts of the review because the listed components are not ordinary dietary supplement ingredients. They belong in a clinician-reviewed conversation. Buyers should not use a marketing page to decide whether any medication pathway is right for them. That decision belongs with a licensed healthcare provider who can review the buyer's specific situation.
A careful buyer should ask direct questions before moving forward. What exact formulation could be prescribed if approved? Which pharmacy may dispense it? What information is included on the medication label? What health conditions or current medications could make the program inappropriate? What instructions should be followed if the medication is dispensed?
The official page may use strong marketing language around the listed components. This review does not adopt that language as an editorial claim. The safer and more useful buyer takeaway is that the components should be discussed with the reviewing provider and dispensing pharmacy before use.
Buyer takeaway: The listed components make provider review especially important. Buyers should confirm exact medication details, instructions, risks, and clinical appropriateness with the licensed provider and pharmacy if approved.
View MEDVi QUAD Program Details
Why the Compounded-Medication Disclosure Matters
Quick answer: The compounded-medication disclosure matters because compounded medications are not FDA-approved finished products. Buyers should confirm the pharmacy, formulation, labeling, instructions, and provider counseling before enrolling in any telehealth program involving compounded medication.
The official MEDVi page includes compounded-medication language and encourages prospective users to speak with their provider about risks and benefits that may come with compounded medication. That is useful language because it gives buyers the right action step: ask questions before using anything prescribed.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before they are marketed. That does not mean every compounded medication is inappropriate. It means compounded medications occupy a different regulatory category than FDA-approved finished drug products, and buyers should understand that difference before enrolling.
In practical terms, buyers should ask who compounds or dispenses the medication, whether the pharmacy is licensed to ship to their state, how the medication is labeled, what instructions are included, and what support is available if questions come up after delivery.
This is not meant to scare the right buyer away. It is meant to help the right buyer move forward with eyes open. The best telehealth decisions happen when convenience and transparency work together.
MEDVi QUAD Pricing: What the Official Page Displays
The official page displayed $114/month at the time reviewed, with $179/month shown as a reference price. Buyers should verify the final checkout amount, billing frequency, cancellation terms, and whether the final charge may vary depending on the prescribed medication and selected pharmacy.
The page also displays doctor consultation included, free rush shipping, 24/7 medical support, and cancel anytime. Those details can make the offer feel simple. Still, the checkout page matters more than the marketing block because final enrollment terms are what the buyer is agreeing to.
MEDVi's terms state that final charges may fluctuate depending on the prescribed medication and chosen pharmacy for order fulfillment. That is why buyers should verify the final amount before submitting payment, not just rely on the first displayed monthly price.
The official page displays a no-hidden-fees message, but buyers should still verify the final checkout amount and review MEDVi's terms because program details, pharmacy fulfillment, and prescribed medication may affect final charges.
Buyer takeaway: The displayed price is an important starting point, but the final checkout screen is the decision point. Buyers should confirm monthly billing, renewal timing, cancellation steps, consult-fee treatment, pharmacy-related charges, and whether future refills can affect cost.
View MEDVi QUAD Program Details
What the MEDVi Terms Say About Payment, Provider Review, and Refunds
MEDVi's terms include several details buyers should understand before enrolling. The terms state that when a user submits information for healthcare services, the user agrees to pay all fees due. The terms also state that medical consult fees are not subject to or eligible for a refund.
The terms further state that final charges may fluctuate depending on the prescribed medication and selected pharmacy for order fulfillment. They also state that MEDVi-affiliated medical professional entities are out-of-network providers, and that prescription medication or laboratory services ordered through a MEDVi medical provider may not be covered.
For the reader, the practical message is straightforward: do not guess. Verify. Before enrolling, buyers should understand when they are charged, whether any consult portion is non-refundable, whether approval affects payment, how cancellation works, and what happens if a provider does not approve the request.
That does not make the program unusual by itself. Many telehealth programs have consult fees, pharmacy fulfillment steps, and eligibility requirements. What matters is whether the buyer reviews those terms before submitting payment instead of trying to sort them out later.
Quick answer: MEDVi's payment and refund language should be reviewed before enrollment because consult fees, final charges, pharmacy fulfillment, and out-of-network status may affect the buyer's cost. Buyers should verify payment timing, cancellation steps, and refund rules before submitting information.
FDA Warning Letter Context: What Buyers Should Know About MEDVi's Broader Marketing History
The FDA issued a February 20, 2026 warning letter to MEDVi, LLC dba MEDVi involving website claims related to compounded semaglutide and tirzepatide products. That letter is relevant context for buyers evaluating MEDVi's broader telehealth marketing, but it should not be represented as a QUAD-specific enforcement finding unless a primary source states that directly.
This distinction matters. It would be inaccurate to say the FDA warning letter was about QUAD unless a primary source says that. It would also be incomplete to ignore the letter entirely when buyers are already searching for MEDVi QUAD FDA warning letter context.
The balanced interpretation is this: the warning letter is part of MEDVi's broader public record and can help buyers understand why careful verification matters with compounded telehealth programs. It is not, based on the reviewed FDA letter, a QUAD-specific conclusion.
For buyers, the useful next step is not panic. It is better due diligence. Ask which provider reviews the request. Ask which pharmacy may fulfill the prescription. Ask what will appear on the label. Ask how the medication is explained if approved. Ask what risks and alternatives should be discussed.
Buyer takeaway: Readers looking for MEDVi QUAD FDA warning letter context should understand the difference between company-level marketing history and product-specific findings. The FDA warning letter should be used as a prompt to verify details, not as a substitute for careful review.
MEDVi QUAD Complaints: Billing, Expectations, and Verification Questions
Search interest around MEDVi QUAD complaints often centers on billing, eligibility, provider review, pharmacy fulfillment, cancellation, and whether checkout terms match the marketing page.
Those are exactly the right areas to check before enrollment. Most buyer frustration in telehealth does not come from reading too much before purchase. It comes from skipping the details and discovering later that billing, cancellation, approval, or pharmacy fulfillment worked differently than expected.
The most useful complaint-prevention step is simple: document the transaction. Save the pricing page. Review the final checkout amount. Read the cancellation language. Keep confirmation emails. Ask support how cancellation works before enrolling if the terms are unclear.
Buyers should also separate marketing expectations from provider review. A marketing page can explain a program, but it cannot decide whether a prescription pathway is appropriate for an individual buyer. That decision requires clinical review.
MEDVi lists customer support details on the official page, including hello@medvi.org and +1-585-312-4226. Buyers with price, billing, or cancellation questions should use those channels before enrollment.
View MEDVi QUAD Program Details
Who Should Speak With a Licensed Provider Before Considering MEDVi QUAD?
Anyone considering MEDVi QUAD should speak with a licensed provider before using any prescription medication. That is not just a disclaimer. It is the core of the buying decision.
The provider should know the buyer's health history, current medications, allergies, prior adverse reactions, cardiovascular history, blood pressure concerns, kidney or liver concerns, and any other medical factors that may affect whether a prescription pathway is appropriate.
Buyers should also ask what medications or health conditions could make the program unsuitable, what adverse-event questions should be discussed, what instructions should be followed if approved, and what to do if any unexpected symptoms occur after use.
This is where the best buyer fit happens. A good match is not just someone who likes the offer. A good match is someone who understands the process, answers the intake accurately, reviews the terms, and discusses medical questions with the licensed provider.
Buyer takeaway: The right buyer is not trying to bypass medical review. The right buyer wants privacy, convenience, and a provider-guided process while still taking the prescription pathway seriously.
Where Can Buyers Access MEDVi QUAD?
Buyers can review MEDVi QUAD through the official website at https://quad.medvi.org/ or through the affiliate access link provided for this placement: https://communityhealthcarenetwork.org/quad-by-medvi.
Before entering personal or payment information, buyers should confirm they are on a secure page, review the displayed program terms, check the contact information, and compare the final checkout details with the pricing language shown earlier in the process.
Buyers should be cautious with copied social-media links, comment-section links, or pages that do not clearly show MEDVi branding and contact details. The official website and affiliate access path are the cleanest places to verify the current offer.
View MEDVi QUAD Program Details
Additional MEDVi QUAD Coverage Readers May Compare
Readers who want more context can compare additional MEDVi QUAD coverage that discusses compounded prescription facts, buyer verification, complaint-related search interest, FDA warning-letter context, and questions to review before enrollment. These resources should be used as supplemental reading, not as a substitute for reviewing the official MEDVi page, current checkout terms, and provider guidance.
Earlier buyer-verification coverage on billing, complaint searches, and FDA-warning-letter context
Earlier coverage on compounded prescription facts and enrollment verification
Additional background coverage on MEDVi, public marketing context, and FDA-warning-letter discussion
Buyer takeaway: Additional coverage can help buyers understand the broader search conversation, but the official website, checkout page, licensed provider, and dispensing pharmacy are the sources that matter most before enrollment.
MEDVi Contact Information and Customer Support
The official MEDVi QUAD page lists the following contact information:
MEDVi Email: hello@medvi.org
MEDVi Phone: +1-585-312-4226
MEDVi Mailing Address: 131 Continental Dr. Ste 305, Newark, DE 19713 USA
Official Website: https://quad.medvi.org/
Customer support can help with account, billing, access, and program questions. Medical questions should be directed to the licensed provider or dispensing pharmacy involved in the prescription process if approved.
Before enrolling, buyers may want to contact support and ask how cancellation works, whether consult fees are refundable, whether the displayed price can change, when billing renews, and what happens if the buyer does not qualify after provider review.
20 Questions to Ask Before Enrolling
This checklist is the best way to turn curiosity into a confident decision. Buyers do not need to be experts. They just need clear answers before they submit payment.
Is the displayed monthly price still the same when the buyer reaches checkout?
Does checkout show a different recurring price, bundled price, or first-month charge?
What exact medication strength and dosage form is prescribed if approved?
Which licensed provider or medical group reviews the intake?
Which pharmacy fulfills the prescription if approved?
Is the pharmacy licensed in the buyer's state?
Is the formulation compounded or commercially manufactured?
Does the buyer understand that compounded medications are not FDA-approved finished products?
Does approval require a health history review?
Can the provider decline treatment if not clinically appropriate?
Are consult fees refundable or non-refundable?
Does cancellation require portal messaging, email, phone, or another process?
When does billing renew?
Is the buyer charged before or after provider review?
Does the order include rush shipping, and are there any limitations?
What happens if the buyer does not qualify?
What adverse-event or interaction questions should be discussed with the provider?
What medications or health conditions should be disclosed before review?
Is customer support reachable by both email and phone?
Does the buyer have written confirmation of the price, cancellation terms, and provider decision before proceeding?
Buyer takeaway: The strongest buyers are not the ones who skip questions. They are the ones who verify the program first, understand the terms, and move forward only when the provider-review process and payment details make sense.
View MEDVi QUAD Program Details
Frequently Asked Questions About MEDVi QUAD
Is Quad by Medvi the same as MEDVi QUAD?
Quad by Medvi is a common search phrasing buyers may use when looking for MEDVi QUAD. This article uses both phrases to help readers identify the same official telehealth prescription program, while focusing on pricing, provider review, pharmacy fulfillment, cancellation terms, and compounded-medication disclosures before enrollment.
What should buyers verify before paying for MEDVi QUAD?
Buyers should verify the final checkout price, billing frequency, provider-review requirement, pharmacy fulfillment process, cancellation method, consult-fee treatment, and compounded-medication disclosure before submitting payment. These details can affect whether the program fits the buyer's expectations.
Why should buyers check MEDVi QUAD terms before enrollment?
Buyers should check MEDVi QUAD terms before enrollment because telehealth prescription programs can involve provider approval, pharmacy fulfillment, recurring billing, consult-fee rules, and cancellation steps. Reviewing those details before payment helps reduce confusion later.
Is MEDVi QUAD a prescription program?
Yes. MEDVi QUAD is presented as a telehealth prescription program. The official page describes an online intake process followed by review from a U.S.-licensed doctor. Prescription medication is available only after consultation with and approval by a licensed healthcare provider, if clinically appropriate.
Is MEDVi QUAD FDA-approved?
MEDVi QUAD should not be described as an FDA-approved finished product based on the information reviewed. The official page refers to a compounded prescription pathway, and FDA explains that compounded drugs are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
How much does MEDVi QUAD cost?
The official page displayed $114/month at the time reviewed, with $179/month shown as a reference price. Buyers should verify the final checkout amount, billing frequency, cancellation terms, and whether the final charge may vary depending on the prescribed medication and selected pharmacy.
Does completing the MEDVi intake guarantee approval?
No. Completing the MEDVi intake should not be understood as guaranteed approval. A licensed provider must review the submitted information and determine whether a prescription pathway is clinically appropriate. Buyers should ask what happens if they do not qualify.
What components are listed for MEDVi QUAD?
The official page lists apomorphine, vardenafil, tadalafil, and sildenafil as components associated with the QUAD compounded prescription program. This article does not compare those components, rank them against alternatives, or make an independent claim about clinical performance. Buyers should confirm the exact formulation, strength, dosage form, pharmacy, instructions, risks, and clinical appropriateness directly with the reviewing provider and dispensing pharmacy if approved.
What should buyers verify before enrolling?
Buyers should verify the final checkout price, billing frequency, cancellation process, consult-fee rules, provider-review process, pharmacy fulfillment, medication labeling, and compounded-medication disclosure. Those details matter more than the first impression created by an ad or landing page.
What does the FDA warning letter mean for MEDVi QUAD buyers?
The FDA issued a February 20, 2026 warning letter to MEDVi involving website claims related to compounded semaglutide and tirzepatide products. That letter is relevant context for buyers evaluating MEDVi's broader telehealth marketing history, but it should not be represented as a QUAD-specific enforcement finding unless a primary source states that directly.
Where should buyers go to access MEDVi QUAD?
Buyers should use the official MEDVi QUAD website or the affiliate access link provided in this placement. The official website is https://quad.medvi.org/. The affiliate access link is https://communityhealthcarenetwork.org/quad-by-medvi. Buyers should verify secure checkout, current pricing, and terms before submitting payment.
What should buyers do if they have medical questions?
Medical questions should be discussed with a licensed healthcare provider. Customer support may help with billing, account access, and program questions, but medication-specific questions should be directed to the reviewing provider or dispensing pharmacy if approved.
Final Verdict: Is MEDVi QUAD Worth Considering?
MEDVi QUAD, also searched as Quad by Medvi, may be worth considering for adults who want a private telehealth evaluation and understand that the process depends on licensed provider review. The strongest appeal is convenience: online intake, provider review, discreet delivery if approved, and support access are all part of the official page's positioning.
The strongest reason to slow down is not fear. It is precision. MEDVi QUAD involves a compounded prescription pathway, and buyers should understand the provider-review process, pharmacy role, pricing terms, cancellation steps, and FDA compounded-medication disclosure before enrolling.
For an appropriate candidate, this kind of program may provide a private and structured way to begin a clinician-reviewed conversation, subject to provider approval. For the wrong buyer, especially someone who wants guaranteed approval, guaranteed outcomes, or a no-questions-asked retail checkout, the program may not match expectations.
The best next step is simple: review the official program details, compare the displayed price with the final checkout terms, and ask MEDVi support, the reviewing provider, or the dispensing pharmacy any questions that are not answered clearly before payment.
View MEDVi QUAD Program Details
Important Disclosures
Medical Disclaimer: This content is for informational and advertising purposes only and is not medical advice, diagnosis, or treatment. Readers should consult a licensed healthcare provider before starting, stopping, or changing any medication or treatment plan.
Prescription and Telehealth Disclaimer: Prescription medication is available only after consultation with and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed. MEDVi is described in its terms as a platform that supports administrative and technology functions. Independent providers are responsible for clinical decisions.
Compounded Medication Disclaimer: Compounded medications are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Patients should ask the prescribing provider and dispensing pharmacy about risks, benefits, alternatives, dosing, labeling, and monitoring.
Affiliate Disclosure: This content contains affiliate links. If a reader purchases or enrolls through links in this content, a commission may be earned at no additional cost to the reader.
Advertising Disclosure: This content may be distributed as an advertorial or sponsored consumer-information feature. The sponsored publisher may receive compensation for distribution or referral activity.
Results Disclaimer: Individual experiences vary. No outcome is guaranteed. Any customer feedback, rating, or testimonial reference should be understood as individual experience, not a promise of similar results.
Pricing Disclaimer: Pricing, availability, eligibility, shipping, cancellation terms, and program details may change. The official page may display promotional pricing, reference pricing, bundled pricing, or checkout terms that differ by timing, eligibility, prescription decision, pharmacy fulfillment, or program selection. Buyers should verify all terms on the official website and at checkout before submitting payment.
FDA Warning Letter Context Disclaimer: Any discussion of FDA warning-letter history should be read in context. The February 20, 2026 FDA warning letter addressed MEDVi website claims related to compounded semaglutide and tirzepatide products and should not be represented as a QUAD-specific enforcement finding unless a source specifically states that.
Trademark Disclaimer: Third-party names and marks belong to their respective owners. Mention does not imply affiliation, endorsement, or sponsorship.
Publisher Liability Disclaimer: The publisher, syndication partners, and distribution platforms are not responsible for typographical errors, changes to brand pages after publication, checkout changes, medical decisions, pharmacy fulfillment, or customer-service outcomes. Readers should verify current information directly with the official provider before making a purchase or enrollment decision.
Email: hello@medvi.org | Phone: +1-585-312-4226
SOURCE: MEDVi
Source: MEDVi
